← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV14행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
AAV9 BBP-812 (AAV9 BBP-812)
Aspa Therapeutics·Canavan Disease
1 trials
Overview
Program
AAV9 BBP-812
Overview
Company
Aspa Therapeutics
Overview
Modality
CGT
Overview
Target
Canavan Disease
Overview
Indication
Canavan Disease
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice.. Type 2 diabetes mellitus (T2DM) has significant treatment challenges due to its complex pathophysiology and associated comorbidities. In recent years, hepatokine fibroblast growth factor 21 (FGF21) has gained significant attention for treatment of metabolic disorders.…
Clinical
Safety signal
Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice.. Type 2 diabetes mellitus (T2DM) has significant treatment challenges due to its complex pathophysiology and associated comorbidities. In recent years, hepatokine fibroblast growth factor 21 (FGF21) has gained significant attention for treatment of metabolic disorders.…
Clinical
Program phase
PHASE_2